Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study.
Wen Xie(University of Pittsburgh), Michael Reiß(Klinikum Bremerhaven-Reinkenheide), Bruce G. Haffty(Rutgers, The State University of New Jersey), David L. Rimm(Yale University), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Robert L. Camp, Daniel Reiss
PubMed
January 15, 2002
Cited by 218
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k